JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Cell lines
Human synoviocytes
Reaction Conditions
10-7 ~ 10-4 M teriflunomide for 50 h incubation
Applications
Teriflunomide inhibited the production of prostaglandin E2 in TNF-α- or IL-1α-stimulated isolated human synoviocytes (IC50s = 7 and 3 μM, respectively). At higher concentrations (> 10 μM), teriflunomide also reduced the production of matrix metalloproteinase 1 and IL-6 due to the known inhibitory effect of teriflunomide on pyrimidine synthesis, which could be reversed by the addition of uridine.
Animal models
Male Dark Agouti (DA) rat, 6-week old
Dosage form
3 and 10 mg/kg
Once daily by oral route
Teriflunomide (3 and 10 mg/kg) delayed disease onset and decreased neurological deficits in a rat model of experimental autoimmune encephalomyelitis induced by complete Freund’s adjuvant and Mycobacterium tuberculosis.
Note
The technical data provided above is for reference only.
References:
1. Burger D, Begué-Pastor N, Benavent S, et al. The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes. Rheumatology (Oxford), 2003, 42(1): 89-96.
2. McMonagle-Strucko K. Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. Journal of Neurology, 2009, 256(1): 89-103.
